How Trump’s Win Could Transform the Pharma

0
147
Trump
Trump

How Trump’s 2024 Election Win Could Transform the Pharmaceutical Industry: Drug Pricing, FDA Changes, and M&A Opportunities

The recent election of Donald J. Trump as President of the United States has significant implications for the pharmaceutical industry. With both the Senate and the House under Republican control, the industry anticipates shifts in healthcare policies, regulatory frameworks, and market dynamics.

Potential Repeal or Modification of the Inflation Reduction Act (IRA)

The Inflation Reduction Act (IRA), enacted during President Biden’s tenure, introduced measures aimed at reducing drug prices, including granting Medicare the authority to negotiate prices for certain medications. The pharmaceutical industry has expressed concerns that these provisions could hinder innovation by reducing revenues necessary for research and development. While a complete repeal of the IRA may face legislative challenges, modifications to its provisions are possible under the new administration. Analysts suggest that healthcare policy might rank lower on President Trump’s legislative agenda compared to his first term, with potential changes focusing on insurance and Medicare Advantage programs.

Regulatory Environment and the Food and Drug Administration (FDA)

The appointment of key personnel to lead health agencies, particularly the FDA, is crucial for the pharmaceutical industry. Robert F. Kennedy Jr., known for his anti-vaccine stance, has been mentioned as a potential candidate for a significant role in health policy. Kennedy has claimed that President Trump promised him control over public health agencies, including the FDA. Such an appointment could lead to substantial changes in regulatory approaches, potentially affecting drug approvals and public health initiatives. However, securing Senate confirmation for such a controversial figure may prove challenging.

Impact on Mergers and Acquisitions (M&A)

The pharmaceutical industry has experienced a wave of mergers and acquisitions in recent years. Under a Republican-led Federal Trade Commission (FTC), there may be a more lenient approach toward M&A activities, potentially facilitating consolidation within the industry. Analysts from BMO Capital Markets have noted that a Trump administration could be more accommodating to biopharma M&A, which may encourage companies to pursue strategic acquisitions to bolster their pipelines and market positions.

Drug Pricing and Market Dynamics

President Trump’s previous tenure included efforts to address high drug prices, such as the proposed Most Favored Nation policy, which aimed to align U.S. drug prices with those of other developed countries. While this policy faced legal challenges and was not implemented, the new administration may revisit strategies to reduce drug costs. The pharmaceutical industry remains cautious, as aggressive pricing reforms could impact profitability and investment in innovation.

Industry Response and Strategic Considerations

The Pharmaceutical Research and Manufacturers of America (PhRMA) has expressed a willingness to collaborate with the new administration to strengthen the innovation ecosystem in the United States. PhRMA’s CEO, Stephen Ubl, emphasized the importance of preserving an environment that fosters the development of new medicines while addressing healthcare system challenges.

Companies are likely to monitor policy developments closely and may adjust their strategies accordingly. This could include reassessing pricing models, exploring partnerships, and engaging in advocacy to influence policy decisions. The potential for regulatory changes may also prompt companies to expedite drug development timelines and seek approvals before new policies are enacted.

Conclusion

The return of Donald Trump to the White House introduces a period of uncertainty and potential transformation for the pharmaceutical industry. Key areas to watch include possible modifications to the Inflation Reduction Act, appointments to health agencies like the FDA, the regulatory stance on mergers and acquisitions, and initiatives aimed at drug pricing. The industry’s ability to adapt to these changes will be crucial in maintaining its role in advancing healthcare and innovation.

Sources include:

Business News India

Trump’s 2024 win: What it means for Indian IT, real estate, pharma, trade

Today — Following a decisive victory in the 2024 US Presidential Election … Trump is unlikely to repeal the Affordable Care Act (ACA), which provides a framework for healthcare coverage and regulation in th…

Sky News

Robert F Kennedy Jr: Who is the man who could become Donald Trump’s …

2 days ago — Robert F Kennedy Jr unsuccessfully stood as a presidential candidate earlier this year, but has more recently become one of Donald Trump’s most prominent backers. In return for his support …

FiercePharma

Election spotlight: As Harris and Trump face off, what’s at stake for pharma?

3 days ago — Election Day is just about here, marking an end to the unpredictable ride that has been the 2024 presidential race following months of fierce campaigning, wild headlines and inescapable TV ads. | Amer…

Forbes

Trump States He’ll Let RFK Jr. ‘Go Wild’ On Health, Food … – Forbes

November 3, 2024 — Donald Trump, the Republican nominee for President, may let Robert F. Kennedy Jr., choose the next leaders of the NIH, CDC, and FDA and “go wild” on health and food. Subscribe To Newsletters BETA

WIRED

RFK Jr. Wants to Reshape US Health Policy. Good Luck With That

October 31, 2024 — Robert F. Kennedy Jr. says he’ll make big changes in the US government if Donald Trump is elected. He may find them hard to pull off, no matter what position he’s appointed to.

POLITICO

A world without seed oils and pesticides? The food industry … – POLITICO

October 31, 2024 — 10/31/2024 02:56 PM EDT. Donald Trump’s embrace of Robert F. Kennedy Jr. and his fringe health theories is triggering a flurry of outreach in Washington and beyond, with powerful ag interests …

Vox

Trump really could empower RFK Jr. to wreck public health

October 31, 2024 — Oct 31, 2024, 11:25 AM PDT. Donald Trump welcomes Robert F. Kennedy Jr. to the stage at a Turning Point Action campaign rally on October 23, 2024, in Duluth, Georgia. Anna Moneymaker/Getty Images …

pharmaphorum

Pills and polls: What the 2024 election means for pharma

October 31, 2024 — Abortion is a major issue this election cycle, and pharma was pulled into it last year when abortion detractors successfully sued in a lower court to reverse the FDA’s longstanding approval of the abo…

Roll Call

Kennedy hints at vast health agency overhaul if Trump elected

October 30, 2024 — Robert F. Kennedy Jr., testifies during the House Judiciary Select Subcommittee on the Weaponization of the Federal Government in 2023. Kennedy has emerged as a major surrogate for former …

ABC News

RFK Jr. says Trump has ‘promised’ him ‘control of the public health …

October 30, 2024 — Kennedy, an anti-vaccine activist, said he’d lead health agencies under Trump. Robert F. Kennedy Jr. said earlier this week that former President Donald Trump has “promised” him “control of the …

E&E News by POLITICO

RFK Jr. claims Trump has pledged to give him ‘control’ of HHS, USDA

October 30, 2024 — An appointment of Kennedy to a Cabinet position like HHS secretary would require Senate confirmation, which could be a significant hurdle. Robert F. Kennedy Jr. said Monday that former President …

INN

Harris vs. Trump: The 2024 US Election, Drug Prices and Healthcare

October 29, 2024 — Figures from the US Department of Health and Human Services show a 15.2 percent increase in the cost of prescription drugs from 2022 to 2023, with an average of US$590 per drug. In the lead up to …

BioSpace

Harris vs. Trump: How Will the Presidential Election Impact Biopharma …

October 29, 2024 — While some analysts say Donald Trump is a wild card when it comes to drug pricing, many argue his presidency would be more positive for the industry overall, as Kamala Harris has her price-cutting sig…

POLITICO

RFK Jr.’s ag future? – POLITICO

October 28, 2024 — Former President Donald Trump confirmed to Joe Rogan in a podcast episode released Friday that Robert F. Kennedy Jr., a former presidential candidate and current MAHA (“Make America Healthy …

PharmaVOICE

Where Big Pharma’s campaign cash is flowing in this election

October 28, 2024 — As Vice President Kamala Harris and former President Donald Trump enter the home stretch of their campaigns, both candidates have been financially supported by an increasingly anxious pharma sector. B…

Pharmaceutical Technology

US Elections: how healthcare could look under a Harris or Trump …

October 18, 2024 — Abigail Beaney October 18, 2024. As 5 November looms, we take a look at how Harris or Trump would impact the US healthcare sector. Image credit: QubixStudio / Shutterstock. With less than three weeks…

AP News

RFK Jr. suggests he’ll have a significant role on agriculture and …

October 16, 2024 — Robert F. Kennedy Jr. is suggesting he will have significant influence on American agriculture policy if Donald Trump is elected president, the latest in a series of roles he has envisioned for himsel…

FiercePharma

A Trump presidency could be a slight positive for pharma: BMO

October 14, 2024 — That’s the takeaway from a recent note by BMO Capital Markets analysts Evan David Seigerman and Kostas Biliouris, Ph.D., as well as a joint interview with them. Still, the Republican candidate may …

PharmaVOICE

As election day nears, Trump and Harris veer in different directions on …

October 14, 2024 — Despite her support for expanding the negotiation program, Harris has garnered significantly more financial backing from the pharma industry. Harris has received more than $5.3 million in campaign con…

The Pharma Letter

Trump vs Harris—who’s on Big Pharma’s side? | Pharmaceutical | The …

September 22, 2024 — In the 2024 US presidential election, health policy will remain a key issue for pharma. Both Donald Trump and Kamala Harris have criticized high drug prices, raising uncertainty for the industry. Whil…

PharmExec

US Pharma and Biotech Summit 2024: The Impact of the … – PharmExec

May 20, 2024 — US Pharma and Biotech Summit 2024. New York City. While the outcome of any presidential election typically has effects on most industries in the United States, the 2024 is expected to be significantly…

PharmExec

US Pharma and Biotech Summit 2024: The 2024 Presidential Election and …

May 20, 2024 — US Pharma and Biotech Summit 2024: The 2024 Presidential Election and the Pharma Industry. In an interview with Pharm Exec Associate Editor Don Tracy, Robert Zirkelback, Chief Public Affairs Officer,…

PharmaVOICE

Biden or Trump: How deeply will 2024’s election outcome impact pharma …

February 20, 2024 — The election is still months away, but campaign promises are solidifying, and signal th